This drug entry is astuband has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Cupric glycinate
- DrugBank Accession Number
- DB11509
- Background
-
Not Available
- Type
- Small Molecule
- Groups
- Vet approved
- Structure
-
Structure for Cupric glycinate (DB11509)
- Weight
-
Average: 211.664
Monoisotopic: 210.978005 - Chemical Formula
- C4H8CuN2O4
- Synonyms
-
- Copper glycinate
- Copper(II) biglycinate
- Copper(II) diglycinate
- Copper(II) glycinate
- Cupric aminoacetate
- Cupric glycinate
Pharmacology
- Indication
-
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning models
with evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets. - Contraindications & Blackbox Warnings
-
Avoid life-threatening adverse drug eventsImprove clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support. - Pharmacodynamics
-
Not Available
- Mechanism of action
- Not Available
- 吸收
-
Not Available
- Volume of distribution
-
Not Available
- Protein binding
-
Not Available
- Metabolism
- Not Available
- 路线的消除
-
Not Available
- Half-life
-
Not Available
- Clearance
-
Not Available
- Adverse Effects
-
Improve decision support & research outcomesWith structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data. - Toxicity
-
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
-
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided byClassyfire
-
- Description
- This compound belongs to the class of organic compounds known as alpha amino acids. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon).
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Alpha amino acids
- Alternative Parents
- Carboxylic acid salts/Amino acids/Monocarboxylic acids and derivatives/Carboxylic acids/Organopnictogen compounds/Organic zwitterions/Organic oxides/Organic copper salts/Monoalkylamines/Hydrocarbon derivatives show 1 more
- Substituents
- Aliphatic acyclic compound/Alpha-amino acid/Amine/Amino acid/Carbonyl group/Carboxylic acid/Carboxylic acid salt/Hydrocarbon derivative/Monocarboxylic acid or derivatives/Organic copper salt show 11 more
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 68VAV8QID7
- CAS number
- 13479-54-4
- InChI Key
- VVYPIVJZLVJPGU-UHFFFAOYSA-L
- InChI
-
InChI=1S/2C2H5NO2.Cu/c2*3-1-2(4)5;/h2*1,3H2,(H,4,5);/q;;+2/p-2
- IUPAC Name
-
copper(2+) bis(2-aminoacetate)
- SMILES
-
[Cu++].NCC([O-])=O.NCC([O-])=O
References
- 一般引用
-
- Arthington JD, Corah LR, Blecha F: The effect of molybdenum-induced copper deficiency on acute-phase protein concentrations, superoxide dismutase activity, leukocyte numbers, and lymphocyte proliferation in beef heifers inoculated with bovine herpesvirus-1. J Anim Sci. 1996 Jan;74(1):211-7. [Article]
- Rabovsky AB, Komarov AM, Ivie JS, Buettner GR: Minimization of free radical damage by metal catalysis of multivitamin/multimineral supplements. Nutr J. 2010 Nov 23;9:61. doi: 10.1186/1475-2891-9-61. [Article]
- Szymanski P, Fraczek T, Markowicz M, Mikiciuk-Olasik E: Development of copper based drugs, radiopharmaceuticals and medical materials. Biometals. 2012 Dec;25(6):1089-112. doi: 10.1007/s10534-012-9578-y. Epub 2012 Aug 23. [Article]
- External Links
Clinical Trials
- Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
-
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
-
Not Available
- Packagers
-
Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
-
Property Value Source Water Solubility 189.0 mg/mL ALOGPS logP -1.5 ALOGPS logP -3.4 Chemaxon logS -0.05 ALOGPS pKa (Strongest Acidic) 2.31 Chemaxon pKa (Strongest Basic) 9.24 Chemaxon Physiological Charge 0 Chemaxon 氢受体Count 3 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 66.15 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 26.84 m3·mol-1 Chemaxon Polarizability 6.25 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon 医学博士DR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at February 26, 2016 17:27 / Updated at June 12, 2020 16:53